Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- Fiscal System Council Approves MOF’s Proposal for NHI Pricing System Reform
November 2, 2015
- MOF Proposes Full Implementation of Cost-Effective Assessments as Precondition for Full-Scale Introduction of Premium for New Drug Development
November 2, 2015
- Takeda’s Hib Vaccine to Be Reported to PAC in December
November 2, 2015
- PAFSC’s 2nd Committee Receives Report on Add’l Indication for Xeloda, Elplat
November 2, 2015
- MOF Asks Fiscal System Council to Issue Conclusion on Market Price Survey for FY2017 Revision “by Mid-2016 at Latest”
November 2, 2015
- 30% of Generic Companies Unable to Prepare Stable Supply Manuals by End of FY2014; MHLW Official Calls for Early Preparation
October 30, 2015
- Chuikyo Agrees to Tweak “Cost per Course of Treatment” Rule for Combo Drugs after Harvoni Debate
October 29, 2015
- Chuikyo Subcommittee Discusses Envisaged HTA Organization
October 29, 2015
- Chuikyo Sees Big Chorus for Further Reforms in Generic Pricing
October 29, 2015
- Some Chuikyo Subcommittee Members Call for Revision of Rules for Pricing of Biosimilars
October 29, 2015
- Commentary: 1st Sakigake Drugs Picked via “Comparative Evaluation”, Will All Qualified Products Get Designated in the Future?
October 28, 2015
- Thrombopenia Added to Clinically Significant ADR List for Daklinza, Sunvepra
October 28, 2015
- MHLW Eager to Expedite Commercialization of Sakigake Products: New Bureau Head
October 28, 2015
- Keytruda, Novel Anti-Flu Drug Join Japan’s First Sakigake Designation List
October 28, 2015
- MHLW to Talk with MIC about Local Tax Grants to Deal with Increased Costs of Flu Vaccines: Health Service Bureau Chief
October 28, 2015
- 6 Drugs Get Sakigake Designation for Fast-Track Review
October 27, 2015
- New Chief of MHLW Health Policy Bureau Vows to Balance Generic Push and Innovation
October 27, 2015
- ICH Revamped as Legal Entity, PMDA’s Tominaga Picked as Vice Assembly Chair
October 27, 2015
- MHLW to Implement Steps to Curb Social Security Spending as Needed: New Top Bureaucrat
October 26, 2015
- MHLW Asks Chuikyo to Revise Evaluation for Antipsychotic Therapies in Large Dosages without Adequate Guidance
October 26, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…